1 BTC
=
- USD
Organovo Holdings Inc.
As of May 30, 2026 at 24:05 UTC
Chart
About Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
Market Statistics
Trading Metrics
How to Buy ONVO
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy ONVO
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesThe global human liver model market is projected to grow at a CAGR of 14.04% from 2025 to 2030, driven by the increasing prevalence of liver diseases, advancements in organ printing technologies, and increased demand for liver cancer therapeutics.
The demand for organoids is being driven by an increased preference for personalized medicine, a rising trend of using organoids as alternatives to animal testing, and their expanding application in cancer research. North America is expected to dominate the global organoids market during the forecast period.
Poster presented at DDW2024 demonstrating the potential of the Company’s clinical-stage compound, FXR314, in combination with tofacitinib for treating IBD.
Organovo will be presenting data on the Company’s lead clinical-stage drug, FXR314 during DDW2024, which is being held in Washington, D.C. May 18-21, 2024